The understanding of Parkinson's disease through genetics and new therapies

Olivier Uwishema*, Helen Onyeaka, Rawa Badri, Ayşe Nazlı Yücel, Ahmet Kayhan Korkusuz, Abayomi Oyeyemi Ajagbe, Amro Abuleil, Céline Chaaya, Baraa H.M. Alhendawi, Elie Chalhoub

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)
67 Downloads (Pure)

Abstract

Introduction: Parkinson's disease is one of the progressive neurodegenerative diseases from which people suffer for years. The mechanism of this disease is associated with a decrease in the number of dopaminergic neurons in the substantia nigra (SN) while Lewy bodies are still present. As a result, both motor—ridity, tremor, and bradykinesia—and non-motor symptoms such as anxiety and depression. Nowadays, it is well known that the cause behind Parkinson's disease is mainly environmental changes, genetic susceptibility, and toxins. Unfortunately, there is no cure for the disease but treatments. The replacement of lost neurons, α-synuclein and apomorphine, is currently being studied for new therapies. This article focuses on history, mechanism, factors causing Parkinson's disease as well as future therapies for the cure of the diseases. Methodology: Data were collected from medical journals published on PubMed, The Lancet, Cells, and Nature Reviews Neurology databases with a predefined search strategy. All articles considering new therapies for Parkinson's disease were considered. Results: The pathophysiology of Parkinson's disease is currently reasonably understood. However, there is no definitive cure so all the treatments focus mainly on reducing or limiting the symptoms. Current treatment studies focus on genetics, replacing lost neurons, α-synuclein and apomorphine. Conclusion: Parkinson's disease is the most common movement disorder worldwide because of the loss of dopaminergic neurons in the substantia nigra. Its symptoms include motor dysfunctions such as rigidity, tremor, and bradykinesia and non-motor dysfunctions such as anxiety and depression. Through genetics, environmental changes and toxins analysis, it is now known that future new therapies are working on replacing lost neurons, α-synuclein and apomorphine.

Original languageEnglish
Article numbere2577
Number of pages4
JournalBrain and Behavior
Volume12
Issue number5
Early online date21 Apr 2022
DOIs
Publication statusPublished - May 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.

Keywords

  • genetic
  • Parkinson's disease
  • PD
  • therapy

ASJC Scopus subject areas

  • Behavioral Neuroscience

Fingerprint

Dive into the research topics of 'The understanding of Parkinson's disease through genetics and new therapies'. Together they form a unique fingerprint.

Cite this